Polycystic Ovarian Syndrome (PCOS) Therapeutics

Nov. 16, 2011 - PRLog -- GlobalData estimates that the global polycystic ovarian syndrome (PCOS) therapeutics market was valued at $656m in 2010. It is expected to grow at a static compound annual growth rate (CAGR) of 2.6%
over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to the expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia, will drive steady growth in the PCOS therapeutics market. Although the number of treated patients is increasing, the market is experiencing static growth because of the lack of availability of FDA-approved products and the presence of off-label and generic products for treatment. These have lower patient satisfaction levels due to lower efficacy profiles since these products cannot treat all the conditions associated with PCOS such as hyperandrogenism, infertility, hyperglycemia and hirsutism. A large unmet need exists in the management of treatment patterns with the help of more efficacious, cure-all products.

The etiology and pathology of PCOS is not clearly understood. Therefore it is difficult to identify the cause of the disease and develop a drug against it, which means that the current therapies rely on treating the symptoms rather than the disease.

The majority of participants in the PCOS therapeutics pipeline are institutions or universities. Company participation is low because most of the drugs under trial are generics and already being used for this indication, either alone or in combination. Therefore, the current pipeline products are unlikely to impact the market significantly

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData’s research indicates that the current treatment options are focused on offering relief from the conditions associated with PCOS, such as hyperandrogenism, infertility, hyperglycemia and hirsutism. Since there is no approved drug in the market and treatment of PCOS relies upon generic and off-label products with lower efficacy but good safety profiles, a high unmet need exists in the market. This unmet need could be served by modifying the management pattern of the disease through the use of more efficacious products that can treat the conditions associated with PCOS.

The PCOS therapeutics pipeline lacks promising molecules which can address the unmet need of the market by treating all the conditions of PCOS with better efficacy. Therefore market growth will not have any impact on the pipeline in future forecasts

GlobalData, the industry analysis specialist, has released its new report, “Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global PCOS market. It identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, it provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Poly...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.